EATG » Projects » HIVACAR – EVALUATING A COMBINATION OF IMMUNE-BASED THERAPIES TO ACHIEVE A FUNCTIONAL CURE OF HIV INFECTION

HIVACAR – EVALUATING A COMBINATION OF IMMUNE-BASED THERAPIES TO ACHIEVE A FUNCTIONAL CURE OF HIV INFECTION

Project aim: the project aims at changing the current paradigm of HIV treatment by obtaining a functional cure for HIV thanks to effectively targeting residual virus replication and viral reservoirs.

Project leader: Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

Main partners: eTHERNA NV (eTheRNA), Belgium, Fundació Privada Institut de Recerca de La Sida-Caixa (IRSICAIXA), Spain, Aarhus University Hospital Skejby, Denmark Institute of Clinical Medicine, Aarhus University (AARHUS), Denmark, Vrije Universiteit Brussel (VUB), Belgium, Laboratory of Molecular Immunology, The Rockefeller University (LMI), US, Centro Nacional de Biotecnología, CSIC (CNB), Spain, Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia Centre for Excellence in HIV/AIDS (SFU), Canada, EATG, Facultad de Ciencias Económicas y Empresariales. Universidad Complutense de Madrid (UCM), Spain, European Clinical Research Infrastructure Network- European Clinical Research Consortium (ECRIN-ERIC), France, Asphalion, S.L. (ASPHALION), Spain, Assistance Publique Hôpitaux de Paris (APHP), France, Zabala Innovation Consulting, S.A (ZABALA), Spain

EATG participation: Leader for WP6 (Socio-Economic and Psycho-Social Impact and Patient Engagement) and engaged in WP7 (Dissemination and Exploitation)

Duration: 5 years starting from January 2017

Main funding source/programme: EC H2020, Call H2020-SC1-2016-RTD

Website: http://www.hivacar.org/

EATG contact person(s): Mariana Vicente (EATG Office) at mariana.vicente@eatg.org

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn